Gain Therapeutics CEO provides operational update; Phase 1 trial advancing, cash runway into 2025

Gain Therapeutics, Inc.

Phase 1 SAD/MAD trial of GT-02287 underway; MAD cohort expected to start Q1 2024, completion by mid-2024.
$10.1M gross proceeds from Nov 2023 CMPO/PIPE financing; cash runway into 2025 to fund biomarker proof-of-concept.
Computational platform renamed Magellan, now integrates AI/ML and screens 50B+ chemical compounds.
CTO Dr. Xavi Barril leaving; company searching for Chief Medical Officer for clinical development.
Anticipated milestones: MAD completion, Parkinson's patient cohort Q3 2024, biomarker data late 2024/early 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.